SCHEMBL2051573

SCHEMBL2051573

C=Cc1nn(Cc2nc(C)cs2)c2cccc([N+](=O)[O-])c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.40
DCTPP1 Q9H773 1/20 0.35
ALDH1A1 P00352 5/20 0.35
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 4/20 0.32
HPGD P15428 2/20 0.32
NPC1 O15118 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
SCN9A Q15858 1/20 0.31
BACE1 P56817 1/20 0.31
TDP1 Q9NUW8 2/20 0.31
HTT P42858 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2048271 0.84 CSF1R (0.38) CSF1RDCTPP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2048161 0.82 CSF1R (0.47) CSF1RDCTPP1ALDH1A1
SCHEMBL2049191 0.78 CSF1R (0.39) CSF1RDCTPP1MAPTMAPK1RAB9A
SCHEMBL2050948 0.77 CSF1R (0.41) CSF1RDCTPP1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL12978908 0.76 CSF1R (0.38) CSF1RDCTPP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL12979134 0.76 CSF1R (0.36) CSF1RDCTPP1MAPTLMNANPC1
SCHEMBL2048598 0.72 ALDH1A1 (0.32) CSF1RDCTPP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2046920 0.69 DCTPP1 (0.46) DCTPP1ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL2052873 0.67 DCTPP1 (0.39) CSF1RDCTPP1ALDH1A1SCN9ATDP1
SCHEMBL15554126 0.67 CSF1R (0.42) CSF1RSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102822170-B Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC 2014-12-10 CN disclosed
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 US disclosed
EP-2516433-B1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS ARRAY BIOPHARMA INC (US) 2014-05-21 EP disclosed
CN-102822170-A Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC 2012-12-12 CN disclosed
EP-2516433-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS Array Biopharma, Inc. (US) 2012-10-31 EP disclosed
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors ARRAY BIOPHARMA INC. (US) 2012-10-11 US disclosed
WO-2011079076-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors AFF1, FLI1, F3 CSF1R 17/4885DCTPP1 3473/4885ALDH1A1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.